{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T13:39:53Z","timestamp":1777124393376,"version":"3.51.4"},"reference-count":109,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,17]],"date-time":"2022-07-17T00:00:00Z","timestamp":1658016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.alit.2022.07.005","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T23:25:29Z","timestamp":1662765929000},"page":"459-471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Executive summary: Japanese guidelines for allergic conjunctival diseases 2021"],"prefix":"10.1016","volume":"71","author":[{"given":"Dai","family":"Miyazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuki","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Uchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Namba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Ebihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Takamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4990-6308","authenticated-orcid":false,"given":"Ken","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Fujishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeaki","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2022.07.005_bib1","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.alit.2020.03.005","article-title":"Japanese guidelines for allergic conjunctival diseases 2020","volume":"69","author":"Miyazaki","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.07.005_bib2","first-page":"485","article-title":"[Evaluation of the efficacy of subjective symptoms, objective findings, and of a total tear IgE detection kit in diagnosis of allergic conjunctival diseases]","volume":"116","author":"Shojio","year":"2012","journal-title":"Nippon Ganka Gakkai Zasshi [J Jpn Ophthalmol Soc]"},{"key":"10.1016\/j.alit.2022.07.005_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/all.12986","article-title":"Conjunctival allergen provocation test: guidelines for daily practice","volume":"72","author":"Fauquert","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.alit.2022.07.005_bib4","first-page":"581","article-title":"[Conjunctival provocation test with Dermatophagoides pteronyssinus in the diagnosis of allergic conjunctivitis from house mites]","volume":"24","author":"Bertel","year":"2001","journal-title":"[J Fr Ophtalmol]"},{"key":"10.1016\/j.alit.2022.07.005_bib5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/ICO.0b013e3182000feb","article-title":"Relation between total tear IgE and specific serum IgE in seasonal allergic conjunctivitis","volume":"30","author":"Mimura","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.alit.2022.07.005_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/ICO.0b013e318253214b","article-title":"Relationship between total tear IgE and specific serum IgE in autumnal allergic conjunctivitis","volume":"32","author":"Mimura","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.alit.2022.07.005_bib7","first-page":"625","article-title":"[Survey on allergic conjunctival disease in 2017, Japanese Society of ocular allergology]","volume":"126","author":"Okamoto","year":"2022","journal-title":"Nippon Ganka Gakkai Zasshi [J Jpn Ophthalmol Soc]"},{"key":"10.1016\/j.alit.2022.07.005_bib8","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/01.ico.0000121710.58571.c4","article-title":"Surgical management of corneal plaques in vernal keratoconjunctivitis: a clinicopathologic study","volume":"23","author":"Solomon","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.alit.2022.07.005_bib9","doi-asserted-by":"crossref","first-page":"e00774","DOI":"10.1016\/j.idcr.2020.e00774","article-title":"Conjunctivitis can be the only presenting sign and symptom of COVID-19","volume":"20","author":"Scalinci","year":"2020","journal-title":"IDCases"},{"key":"10.1016\/j.alit.2022.07.005_bib10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-2600(20)30193-4","article-title":"Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures","volume":"8","author":"Hui","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.alit.2022.07.005_bib11","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.anai.2014.07.007","article-title":"Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge","volume":"113","author":"Fujishima","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2022.07.005_bib12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/alr.21491","article-title":"Comparing the effects of ketotifen fumarate eye drops and ketotifen oral pills on symptom severity and quality of life in patients with allergic rhinitis: a double-blind randomized clinical trial","volume":"5","author":"Akhavan","year":"2015","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.alit.2022.07.005_bib13","first-page":"187","article-title":"Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response","volume":"4","author":"Armaly","year":"1965","journal-title":"Invest Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib14","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s10384-020-00774-9","article-title":"Reduced steroid-induced intraocular pressure elevation in tacrolimus-treated refractory allergic ocular diseases","volume":"64","author":"Miyazaki","year":"2020","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.anai.2016.08.030","article-title":"Efficacy and safety of an eye wash solution in allergic conjunctivitis after conjunctival allergen challenge","volume":"117","author":"Yazu","year":"2016","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2022.07.005_bib16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000080937","article-title":"Immunomodulatory therapy in ophthalmology - is there a place for topical application?","volume":"218","author":"Bertelmann","year":"2004","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.alit.2022.07.005_bib17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00003226-200403000-00014","article-title":"Topical cyclosporine in the management of shield ulcers","volume":"23","author":"Cetinkaya","year":"2004","journal-title":"Cornea"},{"key":"10.1016\/j.alit.2022.07.005_bib18","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1542\/peds.2004-1555","article-title":"Long eyelashes in a case series of 93 children with vernal keratoconjunctivitis","volume":"115","author":"Pucci","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.alit.2022.07.005_bib19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/01.ico.0000133994.22392.47","article-title":"Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca","volume":"24","author":"Strong","year":"2005","journal-title":"Cornea"},{"key":"10.1016\/j.alit.2022.07.005_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2332\/allergolint.11-OA-0349","article-title":"Blood level of tacrolimus in patients with severe allergic conjunctivitis treated by 0.1% tacrolimus ophthalmic suspension","volume":"61","author":"Ebihara","year":"2012","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2022.07.005_bib21","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/bjophthalmol-2013-304453","article-title":"Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement","volume":"98","author":"Fukushima","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ophtha.2016.11.002","article-title":"Steroid-sparing effect of 0.1% tacrolimus eye drop for treatment of shield ulcer and corneal epitheliopathy in refractory allergic ocular diseases","volume":"124","author":"Miyazaki","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.alit.2022.07.005_bib23","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1080\/02713683.2019.1600197","article-title":"Topical tacrolimus for chronic allergic conjunctival disease with and without atopic dermatitis","volume":"44","author":"Shoji","year":"2019","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.alit.2022.07.005_bib24","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/jop.2008.0121","article-title":"Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis","volume":"25","author":"Fujishima","year":"2009","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.alit.2022.07.005_bib25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/09286580701299411","article-title":"Topical non-steroidal anti-inflammatory drugs in allergic conjunctivitis: meta-analysis of randomized trial data","volume":"14","author":"Swamy","year":"2007","journal-title":"Ophthalmic Epidemiol"},{"key":"10.1016\/j.alit.2022.07.005_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/0091-6749(94)90069-8","article-title":"Sodium cromoglycate eye drops: regular versus \"as needed\" use in the treatment of seasonal allergic conjunctivitis","volume":"94","author":"Juniper","year":"1994","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2022.07.005_bib27","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jaip.2019.10.011","article-title":"Amelioration of conjunctival giant papillae by dupilumab in patients with atopic keratoconjunctivitis","volume":"8","author":"Fukuda","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.alit.2022.07.005_bib28","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1111\/jdv.16278","article-title":"Dupilumab therapy in a patient with atopic dermatitis and severe atopic keratoconjunctivitis","volume":"34","author":"Gkalpakiotis","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.alit.2022.07.005_bib29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.intimp.2017.11.031","article-title":"Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis","volume":"54","author":"Ou","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.alit.2022.07.005_bib30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.alit.2022.07.005_bib31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2340\/00015555-1532","article-title":"Proactive treatment of adult facial seborrhoeic dermatitis with 0.1% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-centre trial","volume":"93","author":"Kim","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.alit.2022.07.005_bib32","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jdv.14891","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.alit.2022.07.005_bib33","doi-asserted-by":"crossref","first-page":"1524293","DOI":"10.1155\/2020\/1524293","article-title":"Consensus on the clinical approach to moderate-to-severe atopic dermatitis in Spain: a Delphi survey","volume":"2020","author":"Sastre","year":"2020","journal-title":"Dermatol Res Pract"},{"key":"10.1016\/j.alit.2022.07.005_bib34","first-page":"179","article-title":"[Comparative study between 10 and 20 mg of cetirizine in the symptomatic treatment of seasonal allergic rhinoconjunctivitis]","volume":"21","author":"Hernandez","year":"1993","journal-title":"[Allergol Immunopathol (Madr)]"},{"key":"10.1016\/j.alit.2022.07.005_bib35","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/BF01844202","article-title":"Protective effects of deflazacort on allergen-specific conjunctival challenge","volume":"45","author":"Ciprandi","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.alit.2022.07.005_bib36","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0002-9394(14)70073-X","article-title":"Treatment of chronic nonbacterial conjunctivitis with a cyclo-oxygenase inhibitor or a corticosteroid. Pranoprofen Study Group","volume":"117","author":"Notivol","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib37","first-page":"256","article-title":"Controlled comparison of two fluorometholone formulations in the antigen challenge model of allergic conjunctivitis","volume":"21","author":"Harper","year":"1995","journal-title":"CLAO J"},{"key":"10.1016\/j.alit.2022.07.005_bib38","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0002-9394(14)71128-6","article-title":"A\u00a0controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis","volume":"123","author":"Dell","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0091-6749(98)70094-6","article-title":"A\u00a0randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis","volume":"102","author":"Dell","year":"1998","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2022.07.005_bib40","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0161-6420(99)90077-5","article-title":"A\u00a0randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis","volume":"106","author":"Shulman","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.alit.2022.07.005_bib41","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1177\/112067211002000501","article-title":"Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study","volume":"20","author":"Figus","year":"2010","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib42","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/jop.2009.0087","article-title":"A\u00a0randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis","volume":"26","author":"Ohashi","year":"2010","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.alit.2022.07.005_bib43","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.clinthera.2012.04.024","article-title":"Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients","volume":"34","author":"Gong","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.alit.2022.07.005_bib44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/2229-516X.96799","article-title":"Comparative study of the ocular efficacy and safety of diclofenac sodium (0.1%) ophthalmic solution with that of ketorolac tromethamine (0.5%) ophthalmic solution in patients with acute seasonal allergic conjunctivitis","volume":"2","author":"Dehar","year":"2012","journal-title":"Int J Appl Basic Med Res"},{"key":"10.1016\/j.alit.2022.07.005_bib45","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/ICO.0b013e318265684b","article-title":"Comparative evaluation of topical pranoprofen and fluorometholone in cases with chronic allergic conjunctivitis","volume":"32","author":"Li","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.alit.2022.07.005_bib46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/02713683.2013.827213","article-title":"Comparative evaluation of olopatadine 0.01% combined fluorometholone 0.1% treatment versus olopatadine 0.01% combined ketorolac 0.4% treatment in patients with acute seasonal allergic conjunctivitis","volume":"39","author":"Celik","year":"2014","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.alit.2022.07.005_bib47","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.anai.2014.11.012","article-title":"Efficacy of daily intranasal fluticasone propionate on ocular symptoms associated with seasonal allergic rhinitis","volume":"114","author":"Ratner","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2022.07.005_bib48","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1185\/03007995.2015.1058250","article-title":"Loteprednol etabonate in the treatment of allergic conjunctivitis: a meta-analysis","volume":"31","author":"Wu","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.alit.2022.07.005_bib49","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/alr.21882","article-title":"Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study","volume":"7","author":"Liu","year":"2017","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.alit.2022.07.005_bib50","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0002-9394(14)70271-5","article-title":"Supratarsal injection of corticosteroid in the treatment of refractory vernal keratoconjunctivitis","volume":"121","author":"Holsclaw","year":"1996","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/eye.1998.67","article-title":"Effects of lodoxamide, disodium cromoglycate and fluorometholone on tear leukotriene levels in vernal keratoconjunctivitis","volume":"12","author":"Akman","year":"1998","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.alit.2022.07.005_bib52","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bjo.83.2.180","article-title":"Efficacy of nedocromil 2% versus fluorometholone 0.1%: a randomised, double masked trial comparing the effects on severe vernal keratoconjunctivitis","volume":"83","author":"Tabbara","year":"1999","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib53","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1034\/j.1600-0420.1999.770505.x","article-title":"Efficacy of supratarsal dexamethasone versus triamcinolone injection in recalcitrant vernal keratoconjunctivitis","volume":"77","author":"Saini","year":"1999","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.alit.2022.07.005_bib54","first-page":"241","article-title":"Supratarsal injection of corticosteroids in the treatment of refractory vernal keratoconjunctivitis","volume":"49","author":"Singh","year":"2001","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib55","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1136\/bjo.2005.082461","article-title":"Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis","volume":"90","author":"Daniell","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib56","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/bjo.2007.122044","article-title":"Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis","volume":"91","author":"Mantelli","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib57","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000099294","article-title":"Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis","volume":"221","author":"Uchio","year":"2007","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.alit.2022.07.005_bib58","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3109\/15569527.2010.484823","article-title":"Hyposensitization in the treatment of resistant cases of vernal keratoconjunctivitis","volume":"29","author":"Mahdy","year":"2010","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.alit.2022.07.005_bib59","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/bjophthalmol-2011-300415","article-title":"Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda, Central Africa: a prospective, randomised, double-masked, controlled clinical trial","volume":"96","author":"De Smedt","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib60","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s10384-012-0152-5","article-title":"Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety","volume":"56","author":"Oner","year":"2012","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib61","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1517\/17425255.2014.884070","article-title":"Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis","volume":"10","author":"Wan","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.alit.2022.07.005_bib62","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/pai.12360","article-title":"Tacrolimus vs. cyclosporine eyedrops in severe cyclosporine-resistant vernal keratoconjunctivitis: a randomized, comparative, double-blind, crossover study","volume":"26","author":"Pucci","year":"2015","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.alit.2022.07.005_bib63","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5935\/0004-2749.20170038","article-title":"Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial","volume":"80","author":"Muller","year":"2017","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib64","first-page":"205","article-title":"Topical flurbiprofen therapy in vernal keratoconjunctivitis","volume":"49","author":"Sud","year":"1995","journal-title":"Indian J Med Sci"},{"key":"10.1016\/j.alit.2022.07.005_bib65","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/bjo.67.10.688","article-title":"Vernal keratoconjunctivitis in the black child and its response to therapy","volume":"67","author":"Dahan","year":"1983","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib66","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1442-9071.1986.tb00044.x","article-title":"Evaluation of sodium cromoglycate and medrysone in the management of atopic keratoconjunctivitis: a double masked clinical study","volume":"14","author":"Vajpayee","year":"1986","journal-title":"Aust N Z J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib67","first-page":"CD009078","article-title":"Topical cyclosporine for atopic keratoconjunctivitis","author":"Gonzalez-Lopez","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.alit.2022.07.005_bib68","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/0002-9394(86)90819-6","article-title":"Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis","volume":"101","author":"BenEzra","year":"1986","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib69","first-page":"644","article-title":"Treatment of severe vernal keratoconjunctivitis with cyclosporine A eyedrops","volume":"20","author":"BenEzra","year":"1988","journal-title":"Transpl Proc"},{"key":"10.1016\/j.alit.2022.07.005_bib70","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0002-9394(14)77061-8","article-title":"Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis","volume":"110","author":"Secchi","year":"1990","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib71","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0161-6420(91)32069-4","article-title":"Topical cyclosporine in vernal keratoconjunctivitis","volume":"98","author":"Bleik","year":"1991","journal-title":"Ophthalmology"},{"key":"10.1016\/j.alit.2022.07.005_bib72","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00003226-199309000-00008","article-title":"Topical cyclosporin A in the treatment of anterior segment inflammatory disease","volume":"12","author":"Holland","year":"1993","journal-title":"Cornea"},{"key":"10.1016\/j.alit.2022.07.005_bib73","first-page":"182","article-title":"Therapeutic use of topical cyclosporine","volume":"25","author":"Kaan","year":"1993","journal-title":"Ann Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/eye.1997.14","article-title":"Topical cyclosporin A 2% in the treatment of vernal keratoconjunctivitis","volume":"11","author":"Mendicute","year":"1997","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.alit.2022.07.005_bib75","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/eye.2001.10","article-title":"Topical cyclosporin A in the management of vernal keratoconjunctivitis","volume":"15","author":"Gupta","year":"2001","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.alit.2022.07.005_bib76","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1081-1206(10)61958-8","article-title":"Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis","volume":"89","author":"Pucci","year":"2002","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2022.07.005_bib77","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00347-001-0600-y","article-title":"[Cyclosporin A 2% eyedrops in therapy of atopic and vernal keratoconjunctivitis]","volume":"99","author":"Tomida","year":"2002","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.alit.2022.07.005_bib78","first-page":"190","article-title":"Topical cyclosporine 0.5 per cent and preservative-free ketorolac tromethamine 0.5 per cent in vernal keratoconjunctivitis","volume":"87","author":"Kosrirukvongs","year":"2004","journal-title":"J\u00a0Med Assoc Thai"},{"key":"10.1016\/j.alit.2022.07.005_bib79","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1399-3038.2006.00427.x","article-title":"Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood","volume":"17","author":"Spadavecchia","year":"2006","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.alit.2022.07.005_bib80","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3129\/i06-061","article-title":"Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis","volume":"41","author":"Kilic","year":"2006","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib81","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/ICO.0b013e318172fbb1","article-title":"Use of systemic T-lymphocyte signal transduction inhibitors in the treatment of atopic keratoconjunctivitis","volume":"27","author":"Anzaar","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.alit.2022.07.005_bib82","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/jop.2008.0103","article-title":"A\u00a0large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis","volume":"25","author":"Ebihara","year":"2009","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.alit.2022.07.005_bib83","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/039463201002300322","article-title":"Long-term safety and efficacy of topical cyclosporine in 156 children with vernal keratoconjunctivitis","volume":"23","author":"Pucci","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.alit.2022.07.005_bib84","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1399-3038.2009.00948.x","article-title":"Treatment of severe vernal keratoconjunctivitis with 1% topical cyclosporine in an Italian cohort of 197 children","volume":"21","author":"Tesse","year":"2010","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.alit.2022.07.005_bib85","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2011.07.004","article-title":"Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study","volume":"128","author":"Lambiase","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.alit.2022.07.005_bib86","doi-asserted-by":"crossref","first-page":"455","DOI":"10.17219\/acem\/37145","article-title":"Topical cyclosporine a 0.05% eyedrops in the treatment of vernal keratoconjunctivitis - randomized placebo-controlled trial","volume":"23","author":"Keklikci","year":"2014","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.alit.2022.07.005_bib87","first-page":"410","article-title":"Efficacy of topical 0.05% cyclosporine treatment in children with severe vernal keratoconjunctivitis","volume":"56","author":"Coban-Karatas","year":"2014","journal-title":"Turk J Pediatr"},{"key":"10.1016\/j.alit.2022.07.005_bib88","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jfo.2015.02.008","article-title":"[Cyclosporine eye drops: a 4-year retrospective study (2009-2013)]","volume":"38","author":"Kauss Hornecker","year":"2015","journal-title":"J\u00a0Fr Ophtalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib89","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ophtha.2003.05.035","article-title":"A\u00a0randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis","volume":"111","author":"Akpek","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.alit.2022.07.005_bib90","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ophtha.2018.12.027","article-title":"A\u00a0randomized, controlled trial of cyclosporine A cationic emulsion in pediatric vernal keratoconjunctivitis: the VEKTIS study","volume":"126","author":"Leonardi","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.alit.2022.07.005_bib91","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0161-6420(98)99043-1","article-title":"A\u00a0randomized, placebo-controlled trial of topical cyclosporin a in steroid-dependent atopic keratoconjunctivitis","volume":"105","author":"Hingorani","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.alit.2022.07.005_bib92","first-page":"25","article-title":"Vernal keratoconjunctivitis in Thailand","volume":"21","author":"Kosrirukvongs","year":"2003","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.alit.2022.07.005_bib93","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0181-5512(07)91357-1","article-title":"[Efficacy of topical 2% cyclosporine A as a steroid-sparing agent in steroid-dependent vernal keratoconjunctivitis]","volume":"30","author":"Doan","year":"2007","journal-title":"[J Fr Ophtalmol]"},{"key":"10.1016\/j.alit.2022.07.005_bib94","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/ICO.0b013e31812dfab3","article-title":"Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops","volume":"26","author":"Ozcan","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.alit.2022.07.005_bib95","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/ICO.0b013e31822481c2","article-title":"Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis","volume":"31","author":"Tzu","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.alit.2022.07.005_bib96","first-page":"177","article-title":"A\u00a0double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children","volume":"30","author":"Labcharoenwongs","year":"2012","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.alit.2022.07.005_bib97","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/ICO.0b013e31828ffdf8","article-title":"Tear cytokine levels in vernal keratoconjunctivitis: the effect of topical 0.05% cyclosporine a therapy","volume":"32","author":"Oray","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.alit.2022.07.005_bib98","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.ophtha.2013.03.044","article-title":"Topical cyclosporine in the treatment of allergic conjunctivitis: a meta-analysis","volume":"120","author":"Wan","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.alit.2022.07.005_bib99","doi-asserted-by":"crossref","first-page":"396987","DOI":"10.1155\/2014\/396987","article-title":"Retrospective review on the use of topical cyclosporin a 0.05% for paediatric allergic conjunctivitis in Hong Kong Chinese","volume":"2014","author":"Wu","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.alit.2022.07.005_bib100","doi-asserted-by":"crossref","first-page":"507","DOI":"10.11622\/smedj.2015161","article-title":"Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis","volume":"57","author":"Yucel","year":"2016","journal-title":"Singapore Med J"},{"key":"10.1016\/j.alit.2022.07.005_bib101","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3126\/nepjoph.v9i2.19257","article-title":"Tacrolimus versus cyclosporine- comparative evaluation as first line drug in vernal keratoconjuctivitis","volume":"9","author":"Kumari","year":"2017","journal-title":"Nepal J Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib102","first-page":"363","article-title":"Vernal shield ulcers treated with frequently installed topical cyclosporine 0.05% eyedrops","volume":"38","author":"Westland","year":"2018","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.alit.2022.07.005_bib103","first-page":"508","article-title":"[A prospective, observational, all-prescribed-patients study of cyclosporine 0.1% ophthalmic solution in the treatment of vernal keratoconjunctivitis]","volume":"115","author":"Takamura","year":"2011","journal-title":"Nippon Ganka Gakkai Zasshi [J Jpn Ophthalmol Soc]"},{"key":"10.1016\/j.alit.2022.07.005_bib104","first-page":"1009","article-title":"[Efficacy of topical cyclosporin therapy in steroid-resistant allergic conjunctivitis]","volume":"17","author":"Hara","year":"2000","journal-title":"Atarashii Ganka [Journal of the Eye]"},{"key":"10.1016\/j.alit.2022.07.005_bib105","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/sj.eye.6702367","article-title":"Tacrolimus ointment vs steroid ointment for eyelid dermatitis in patients with atopic keratoconjunctivitis","volume":"21","author":"Nivenius","year":"2007","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.alit.2022.07.005_bib106","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s12325-012-0031-y","article-title":"Comparison of tacrolimus, fluorometholone, and saline in mild-to-moderate contact lens-induced papillary conjunctivitis","volume":"29","author":"Diao","year":"2012","journal-title":"Adv Ther"},{"key":"10.1016\/j.alit.2022.07.005_bib107","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/ICL.0000000000000001","article-title":"Topical tacrolimus 0.03% as sole therapy in vernal keratoconjunctivitis: a randomized double-masked study","volume":"40","author":"Muller","year":"2014","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.alit.2022.07.005_bib108","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/ICO.0000000000001200","article-title":"Comparative evaluation of tacrolimus versus interferon alpha-2b eye drops in the treatment of vernal keratoconjunctivitis: a randomized, double-masked study","volume":"36","author":"Zanjani","year":"2017","journal-title":"Cornea"},{"key":"10.1016\/j.alit.2022.07.005_bib109","first-page":"378","article-title":"[Follow-up study on patients with vernal keratoconjunctivitis undergoing topical 0.1% tacrolimus treatment]","volume":"118","author":"Harada","year":"2014","journal-title":"Nippon Ganka Gakkai Zasshi [J Jpn Ophthalmol Soc]"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893022000831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893022000831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:12:20Z","timestamp":1761156740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893022000831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":109,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1323893022000831"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2022.07.005","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Executive summary: Japanese guidelines for allergic conjunctival diseases 2021","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2022.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese Society of Allergology. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}